Prelude Therapeutics宣布首创口服Kat6a选择性降解剂PRT13722临床前研究摘要获2026年AACR年会接纳

美股速递
Mar 18

Prelude Therapeutics Inc (PRLD) 宣布,其首创口服Kat6a选择性降解剂PRT13722的临床前研究摘要,已正式获得2026年美国癌症研究协会(AACR)年会的接纳。该突破性疗法旨在通过靶向降解Kat6a蛋白,探索潜在的新型抗癌治疗路径。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10